Navigation Links
Biosignatures distinguish between tuberculosis and sarcoidosis
Date:5/7/2012

This press release is available in German.

With a range of diseases, doctors need unique features which they can use to unequivocally identify a patient's illness for an appropriate diagnosis. Scientists therefore search for the biomarkers for an illness or a combination of biomarkers, known as biosignatures, which are as easy as possible to measure. Researchers at the Max Planck Institute for Infection Biology in Berlin have now created complete gene and microRNA expression profiles together with important inflammatory mediators in the blood of tuberculosis and sarcoidosis patients. Although they have identified a signature that distinguishes healthy individuals from patients, the biosignatures of both diseases are nevertheless very similar. It is almost impossible, therefore, to distinguish between tuberculosis and sarcoidosis with just a single signature. A set of different biosignatures is better suited for distinguishing in a first step between diseased and healthy individuals and, in a further step, between the specific diseases.

Biosignatures cover a profile of different features, which can be used to identify diseases and distinguish them from similar clinical pictures. These features include the presence of mediators and gene expression profiles in the blood. In recent years, for example, researchers have discovered signatures for tuberculosis, which doctors can use to distinguish between patients with tuberculosis and healthy individuals.

Equally important is the distinction between different diseases with similar clinical appearance, such as tuberculosis and sarcoidosis. Therefore, using gene and microRNA expression in blood cells and inflammatory mediators in serum, the scientists at the Max Planck Institute for Infection Biology selected sets of markers characteristic for tuberculosis and sarcoidosis patients. Although both diseases primarily damage the lungs and produce similar symptoms, they have very different causes. While tuberculosis is caused by an infection with bacteria, sarcoidosis is not contagious.

Studies show that the two diseases are not only similar clinically; their biosignatures also have a number of elements in common. Compared to healthy individuals, most genes in sarcoidosis and tuberculosis patients are regulated in a similar way: "Of approximately 13,000 genes whose expression differs, depending on whether the individual is healthy or diseased, approximately 9,000 genes are expressed in the same way in both diseases. Only 700 genes differ in their expression between tuberculosis and sarcoidosis patients but these can be used to unequivocally identify the two diseases," says Stefan Kaufmann from the Max Planck Institute for Infection Biology.

In addition, microRNAs, which modulate the formation of certain proteins by inhibiting gene expression, appear in a similar pattern in both diseases. In total, around 150 microRNAs shared by both diseases differed from healthy individuals. Only four microRNAs are suitable for distinguishing tuberculosis and sarcoidosis patients. The overlap is less pronounced in the profile of inflammatory substances in the blood: while only one of these cytokines is modified equally in tuberculosis and sarcoidosis compared to healthy individuals, twelve of these signal mediators are suitable for distinguishing between the two diseases.

The results obtained by the Berlin researchers show that modified biomarkers can be traced back to processes that occur not only in one specific disease, e.g. immune responses. The immune response therefore draws on the same basic elements in different clinical pictures, and only a few of these elements are specific to a particular disease. These commonalities also reveal a lot to scientists about the general causes and mechanisms underlying many diseases.

A single biosignature is therefore not enough to distinguish between healthy and diseased individuals, and to distinguish between different diseases with a similar clinical phenotype. Although the combination of many genes increases specificity and sensitivity in distinguishing between healthy and diseased individuals, it automatically leads to a lower specificity compared to other clinical pictures. "Instead, we should first of all distinguish between healthy and diseased individuals and then separate the individual diseases from one another in the next steps. We can then unequivocally identify a disease using a handful of genes per step," explains Kaufmann.

This means that doctors could concentrate on diseases that actually occur locally. In African countries, where tuberculosis is widespread, it would then be possible to identify tuberculosis, AIDS and malaria quickly.


'/>"/>
Contact: Stefan H.E. Kaufmann
kaufmann@mpiib-berlin.mpg.de
49-302-846-0500
Max-Planck-Gesellschaft
Source:Eurekalert  

Related biology news :

1. 2 distinguishable gene groups detected: 1 normal and 1 problematic
2. SEBM Distinguished Scientist Awards for 2012
3. Pew announces 2012 recipients of distinguished Marine Conservation Fellowship
4. Gladstone founder receives American Heart Association Distinguished Scientist Award
5. Steven B. Abramson, MD, receives distinguished Basic Investigator Award at ACR 2011
6. Biophysical Society names 2012 Distinguished Service and Emily Gray awardees
7. Salk scientist receives distinguished NIH award for transformative research
8. LLNL selects Madhav Marathe for the first George A. Michael Distinguished Scholar Award
9. BUSM professor selected as American Heart Association Distinguished Scientist
10. Tel Aviv University confers its highest honor on 8 distinguished individuals
11. Pew announces 2011 recipients of distinguished marine conservation fellowship
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biosignatures distinguish between tuberculosis and sarcoidosis
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... February 5, 2016 Amarantus BioScience ... company focused on developing products for Regenerative Medicine, Neurology ... Pediatric Disease Designation (RPDD) from the US Food and ... MANF. MANF was previously granted orphan drug designation (ODD) ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... training, today announced an interactive FDA compliance training course, Writing ... Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on smartphones ...
(Date:2/4/2016)... RICHMOND, Calif. , Feb. 4, 2016  Sangamo ... therapeutic genome editing, announced today that Edward Lanphier ... an update on the progress of Sangamo,s ZFP Therapeutic ... company,s business strategy at 2:40 pm ET on Thursday, ... Annual Global Healthcare Conference. The conference is being ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Bloomsburg University’s Digital Forensics Club, takes place February 5-6 at the University’s ... 20+ speakers and activities such as workshops and competitions for ample networking, ...
Breaking Biology Technology: